Skip to main content

Flu Avert I.N. Vaccine (Canada)

This treatment applies to the following species:
Company: Merck Animal Health

EQUINE INFLUENZA VACCINE, MODIFIED LIVE VIRUS

For Intranasal Use Only

DIRECTIONS FOR USE, READ CAREFULLY

Description

This vaccine is a lyophilized preparation containing an attenuated, cold-adapted, viable equine influenza virus type H3N8 strain (EIV A/Equine 2/Kentucky/91). Contains no preservatives.

Flu Avert I.N. Vaccine Indications

This product has been shown to be effective for the vaccination of healthy horses 11 months of age or older against disease caused by EIV. Duration of immunity has been shown to be at least 6 months. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.

This product contains influenza A/Equine 2/Kentucky/91 (H3N8). Efficacy was demonstrated against A/Equine 2/Kentucky/91 (H3N8) and the duration of immunity was demonstrated against A/Equine/Kentucky/99 (H3N8). This product has been shown to be effective against virus shedding of EIV.

Flu Avert I.N. Vaccine Cautions

Store at 2°-8°C (35°-46°F). Store out of direct sunlight. Do not vaccinate pregnant animals. Do not vaccinate within 21 days before slaughter. Do not mix with other products, except as specified on the label. Inactivate unused contents before disposal. If allergic reaction occurs, treat with epinephrine. We recommend that the vaccine be administered by a veterinarian or a trained technician. A small number of horses may experience mild post-vaccination side effects including slight nasal discharge. These signs should clear in a few days without additional treatment. In case of human exposure, contact a physician.

FOR ANIMAL USE ONLY

Dose

Administer a single 1 mL dose intranasally in one nostril.

NOTE: A new applicator should be used to vaccinate each horse. No needles are necessary to administer the vaccine. This vaccine is NOT intended for intramuscular or subcutaneous injection. For primary immunization, a single dose is required in horses 11 months of age or older. For advice on revaccination frequency, consult your veterinarian.

Rehydration and Administration

Step 1: Attach a sterile needle to a 3 cc luer lock syringe.

Step 2: Use the syringe and needle to withdraw the entire contents of the diluent vial through the rubber stopper.

Step 3: Aseptically insert the needle from the syringe loaded with diluent into the vial of lyophilized vaccine. Transfer the contents from the syringe into the vaccine vial.

Step 4: Mix the diluent and vaccine using a gentle swirling motion. Once dissolved immediately withdraw the full amount of rehydrated vaccine using the syringe and needle.

Step 5: REMOVE THE NEEDLE from the syringe and safely dispose of it. Replace with a nasal applicator. Take care to securely attach the applicator to the luer lock syringe.

Step 6: Place the nasal applicator into the ventral meatus of the nasal passage (see figure 1). Depress the plunger to administer the vaccine. Withdraw and discard the applicator and syringe.

It is normal for a small amount of vaccine to drip from the nasal passage after vaccination.

Please utilize a new applicator for each dose of vaccine.

Intervet Inc. d/b/a Merck Animal Health, Omaha, NE 68103, USA

VLN/PCN 165A/1501.20

1 800 521-5767 (USA)

1 866 683-7838 (Canada)

For patent information:

http://www.merck.com/product/patent/home.html

178484-02

 

Code

 

10 Doses (10x1 dose vials of lyophilized vaccine, 10 vials of sterile diluent and 10 nasal applicators)

197763

197313-02

CPN: 1208185.4

MERCK ANIMAL HEALTH
Intervet Canada Corp.

16750 ROUTE TRANSCANADIENNE, KIRKLAND, QC, H9H 4M7
Order Desk:   514-428-7013
Toll-Free:   866-683-7838
Fax:   Toll-free 888-498-4444; local 514-428-7014
Website:   www.merck-animal-health.ca
THIS SERVICE AND DATA ARE PROVIDED "AS IS". Animalytix assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the Animalytix service and data. See the Terms of Use for further details.

Animalytix

Copyright © 2024 Animalytix LLC. Updated: 2024-11-27